News
Cytokinetics' heart drug omecamtiv strikes out in heart fail...
Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.
